Isabelle Dehaene

Dr. Isabelle Dehaene

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2020 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
IDIsabelle Dehaene
Isabelle Dehaene
ESEline Scheire
Eline Scheire
JSJohan Steen
Johan Steen
KCKris De Coen
Kris De Coen
JDJohan Decruyenaere
Johan Decruyenaere
KRKristien Roelens
Kristien Roelens

1 December 2017 in Seminars in Perinatology
Verified
Journal Article
Closed access
IDIsabelle Dehaene
Isabelle Dehaene
LBLina Bergman
Lina Bergman
PTPaula Turtiainen
Paula Turtiainen
ARAlexandra Ridout
Alexandra Ridout
BMBen Willem Mol
Ben Willem Mol
ELElsa Lorthe
Elsa Lorthe


3 October 2020 in Acta Clinica Belgica
Verified
Journal Article
Closed access
TVThomas Vanassche
Thomas Vanassche
COChristelle Orlando
Christelle Orlando
KVKristel Vandenbosch
Kristel Vandenbosch
AGAlain Gadisseur
Alain Gadisseur
CHCédric Hermans
Cédric Hermans
COCécile Oury
Cécile Oury
COVID-19 predisposes patients to thrombotic disease. The aim of this guidance document is to provide Belgian health-care workers with recommendations on anticoagulation management in COVID-19 posit...

10 May 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
LGLissa van Gils
Lissa van Gils
MBMarjon A de Boer
Marjon A de Boer
JBJudith Bosmans
Judith Bosmans
RDRuben Duijnhoven
Ruben Duijnhoven
SSSam Schoenmakers
Sam Schoenmakers
MOMartijn A Oudijk
Martijn A Oudijk
Introduction Twin pregnancies have a high risk of extreme preterm birth (PTB) at less than 28 weeks of gestation, which is associated with increased risk of neonatal morbidity and mortality. Currently there is a lack of effective treatments for women with a twin pregnancy and a short cervix or cervical dilatation. A possible effective surgical method to reduce extreme PTB in twin pregnancies with an asymptomatic short cervix or dilatation at midpregnancy is the placement of a vaginal cerclage. Methods and analysis We designed two multicentre randomised trials involving eight hospitals in the Netherlands (sites in other countries may be added at a later date). Women older than 16 years with a twin pregnancy at <24 weeks of gestation and an asymptomatic short cervix of ≤25 mm or cervical dilatation will be randomly allocated (1:1) to both trials on vaginal cerclage and standard treatment according to the current Dutch Society of Obstetrics and Gynaecology guideline (no cerclage). Permuted blocks sized 2 and 4 will be used to minimise the risk of disbalance. The primary outcome measure is PTB of <28 weeks. Analyses will be by intention to treat. The first trial is to demonstrate a risk reduction from 25% to 10% in the short cervix group, for which 194 patients need to be recruited. The second trial is to demonstrate a risk reduction from 80% to 35% in the dilatation group and will recruit 44 women. A cost-effectiveness analysis will be performed from a societal perspective. Ethics and dissemination This study has been approved by the Research Ethics Committees in the Netherlands on 3/30/2023. Participants will be required to sign an informed consent form. The results will be presented at conferences and published in a peer-reviewed journal. Participants will be informed about the results. Trial registration number ClinicalTrials.gov, NCT05968794.

1 March 2021 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
IDIsabelle Dehaene
Isabelle Dehaene
ELElsa Lorthe
Elsa Lorthe
LGL. Gurney
L. Gurney
PTP. Turtiainen
P. Turtiainen
ASA. Schwickert
A. Schwickert
LBLina Bergman
Lina Bergman